Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts

Mynarek, M; Obrecht, D; Sill, M; Sturm, D; Kloth-Stachnau, K; Selt, F; Ecker, J; von Hoff, K; Juhnke, BO; Goschzik, T; Pietsch, T; Bockmayr, M; Kool, M; von Deimling, A; Witt, O; Schüller, U; Benesch, M; Gerber, NU; Sahm, F; Jones, DTW; Korshunov, A; Pfister, SM; Rutkowski, S; Milde, T

Mynarek, M (通讯作者),Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Martinistr 52, D-20246 Hamburg, Germany.;Mynarek, M (通讯作者),Univ Med Ctr Hamburg Eppendorf, Mildred Scheel Canc Career Ctr HaTriCS4, Hamburg, Germany.;Milde, T (通讯作者),Hopp Childrens Canc Ctr Heidelberg KiTZ, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.;Milde, T (通讯作者),Heidelberg Univ Hosp, Dept Pediat Hematol & Oncol, Heidelberg, Germany.;Milde, T (通讯作者),German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, Heidelberg, Germany.

ACTA NEUROPATHOLOGICA, 2023; 145 (1): 97

Abstract

Molecular groups of medulloblastoma (MB) are well established. Novel risk stratification parameters include Group 3/4 (non-WNT/non-SHH) methylation su......

Full Text Link